Graphical abstract Necrostatin-1 (Nec-1) is a RIP1-targeted inhibitor of necroptosis, a form of programmed cell death discovered and investigated in recent years. There are already many studies demonstrating the essential role of necroptosis in various diseases, including inflammatory diseases, cardiovascular diseases and neurological diseases. However, the potential of Nec-1 in diseases has not received much attention. Nec-1 is able to inhibit necroptosis signaling pathway and thus ameliorate necroptotic cell death in disease development. Recent research findings indicate that Nec-1 could be applied in several types of diseases to alleviate disease development or improve prognosis. Moreover, we predict that Nec-1 has the potential to protect against the complications of coronavirus disease 2019 (COVID-19). This review summarized the effect of Nec-1 in disease models and the underlying molecular mechanism, providing research evidence for its future application.
【저자키워드】 COVID-19, COVID-19, Coronavirus disease 2019, Anti-inflammation, IL, interleukin, necroptosis, TNF, Tumor Necrosis Factor, AKI, acute kidney injury, NF-κB, Nuclear Factor kappa B, disease models, ROS, reactive oxygen species, ALI, Acute Lung Injury, LPS, lipopolysaccharide, MI, myocardial infarction, SIRS, Systemic Inflammatory Response Syndrome, IDO, Indoleamine 2,3-dioxygenase, AD, Alzheimer’s disease, PD, Parkinson’s disease, GSH, glutathione, HMGB1, high mobility group box 1, DAMPs, damage-associated molecular patterns, ICH, Intracerebral hemorrhage, PRR, pattern recognition receptor, AAA, abdominal aortic aneurysm, ALS, amyotrophic lateral sclerosis, AMD, age-related macular degeneration, CaMKII, Ca2+/calmodulin-dependent protein kinase II, cIAP1/2, cellular inhibitor of apoptosis proteins 1 and 2, Cyp-D, cyclophilin-D, ERS, endoplasmic reticulum stress, FADD, fas associated via death domain, FHF, fulminant hepatic failure, HD, Huntington’s disease, HG, high glucose, HI, hypoxia-ischemia, HIV-1, human immunodeficiency virus type 1, I/R, Ischemia-reperfusion, LDL, low density lipoprotein, LMP, lysosomal membrane permeabilization, MLKL, mixed lineage kinase domain-like protein, MPTP, mitochondrial permeability transition pore, MTH-Trp, methyl-thiohydantoin-tryptophan, mTOR, mechanistic target of rapamycin, Nec-1, Necrostatin-1, Nec-1i, Necrostatin-1 inactive, Nec-1s, Necrostatin-1 stable, ox-LDL, oxidized LDL, PARP1, polymerase 1, PCD, programmed cell death, PYGL, glycogen phosphorylase, RDA, RIP1-dependent apoptosis, RGAG, advanced glycation end products, RGCs, retinal ganglion cells, RIA, RIP1-indipendent apoptosis, RIP1, receptor interacting protein 1, RIP3, receptor interacting protein 3, RPE, retinal pigment epithelial, SAH, subarachnoid Hemorrhage, SCI, spinal cord injury, TBI, traumatic brain injury, TNFR1, TNF receptor 1, TRADD, TNFR-associated death domain, TRAF2, TNFR-associated factor 2, necrostatin-1,